{"id":651209,"date":"2023-05-11T18:30:01","date_gmt":"2023-05-11T18:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=651209"},"modified":"2023-05-11T18:30:01","modified_gmt":"2023-05-11T18:30:01","slug":"liver-cancer-market-and-epidemiology-forecast-2032-population-data-drugs-companies-and-competitive-intelligence-by-delveinsight-pfizer-glaxosmithkline-kyowa-kirin-co-ltd-hoffmannla-roche","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/liver-cancer-market-and-epidemiology-forecast-2032-population-data-drugs-companies-and-competitive-intelligence-by-delveinsight-pfizer-glaxosmithkline-kyowa-kirin-co-ltd-hoffmannla-roche_651209.html","title":{"rendered":"Liver Cancer Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Pfizer, GlaxoSmithKline, Kyowa Kirin Co., Ltd., Hoffmann-La Roche"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1683802449.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Liver Cancer Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Pfizer, GlaxoSmithKline, Kyowa Kirin Co., Ltd., Hoffmann-La Roche\" src=\"https:\/\/www.abnewswire.com\/uploads\/1683802449.jpeg\" alt=\"Liver Cancer Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Pfizer, GlaxoSmithKline, Kyowa Kirin Co., Ltd., Hoffmann-La Roche\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cLiver Cancer Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Liver Cancer.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Liver Cancer Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Liver Cancer, historical and forecasted epidemiology as well as the Liver Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Liver Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/liver-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Liver Cancer Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Liver Cancer Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Liver Cancer market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period <strong>(2019-2032)<\/strong><\/li>\n<li>The Global Cancer Observatory estimates that in the 7MM, the ASR incident rate of liver cancer is <strong>7.4\/100,000,<\/strong> which translates to approximately 135,530 new cases in 2020, and the ASR fatality rate is <strong>4.8\/100,000<\/strong>, which translates to approximately <strong>100,790 fatalities<\/strong> in 2020<\/li>\n<li>According to the Global Cancer Observatory, the incidence rate of liver cancer in Japan is 10.4\/100,000, which corresponds to an estimated <strong>45,660 new cases<\/strong> being diagnosed in 2020, and the incidence rate of liver cancer mortality is <strong>4.8\/100,000<\/strong>, which corresponds to an estimated <strong>28,155 deaths<\/strong> in 2020<\/li>\n<li>In the United States, the incident rate of liver cancer and intrahepatic bile duct cancer was <strong>9.0 per 100,000<\/strong>, translating to an expected <strong>42,230 new cases<\/strong> in 2021, according to Surveillance, Epidemiology, and End Results (SEER)<\/li>\n<li><strong>Key Liver Cancer Companies:<\/strong> Pfizer, GlaxoSmithKline, Kyowa Kirin Co., Ltd., Hoffmann-La Roche, Eli Lilly and Company, Guerbet, CStone Pharmaceuticals, SOTIO Biotech, Akeso Biopharma, Adagene Inc., Tempest Therapeutics, Eximias Pharmaceutical, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Jiangsu HengRui Medicine Co., Ltd., and others<\/li>\n<li><strong>Key Liver Cancer Therapies:<\/strong> Sunitinib (SU011248), TSR-022 and TSR-042, ARQ197, bevacizumab [Avastin], Pemetrexed, Lipiodol, Nofazinlimab, Nanrilkefusp alfa (formerly SOT101), AK112, Bevacizumab, Tiragolumab, doxorubicin hydrochloride, exatecan mesylate, Brivanib, Apatinib, PD-0332991, and others<\/li>\n<li>The Liver Cancer market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Cancer pipeline products will significantly revolutionize the Liver Cancer market dynamics.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Liver Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">One type of cancer that begins in the liver is known as liver cancer. It is the third most common cause of cancer death and the sixth most frequent malignancy to be diagnosed globally. Primary liver cancer primarily manifests as hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Liver Cancer Market Report &#8211;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/liver-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/liver-cancer-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Liver Cancer Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Liver Cancer Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Liver Cancer market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Liver Cancer<\/li>\n<li>Prevalent Cases of Liver Cancer by severity<\/li>\n<li>Gender-specific Prevalence of Liver Cancer<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Liver Cancer<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Liver Cancer epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/liver-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Liver Cancer Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Liver Cancer Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liver Cancer market or expected to get launched during the study period. The analysis covers Liver Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Liver Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Liver Cancer Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Sunitinib (SU011248):<\/strong> Pfizer<\/li>\n<li><strong>TSR-022 and TSR-042:<\/strong> GlaxoSmithKline<\/li>\n<li><strong>ARQ197:<\/strong> Kyowa Kirin Co., Ltd.<\/li>\n<li><strong>bevacizumab [Avastin]:<\/strong> Hoffmann-La Roche<\/li>\n<li><strong>Pemetrexed:<\/strong> Eli Lilly and Company<\/li>\n<li><strong>Lipiodol:<\/strong> Guerbet<\/li>\n<li><strong>Nofazinlimab:<\/strong> CStone Pharmaceuticals<\/li>\n<li><strong>Nanrilkefusp alfa (formerly SOT101):<\/strong> SOTIO Biotech<\/li>\n<li><strong>AK112:<\/strong> Akeso Biopharma<\/li>\n<li><strong>Bevacizumab:<\/strong> Adagene Inc.<\/li>\n<li><strong>Tiragolumab:<\/strong> Tempest Therapeutics<\/li>\n<li><strong>doxorubicin hydrochloride:<\/strong> Eximias Pharmaceutical<\/li>\n<li><strong>exatecan mesylate:<\/strong> Daiichi Sankyo, Inc.<\/li>\n<li><strong>Brivanib:<\/strong> Bristol-Myers Squibb<\/li>\n<li><strong>Apatinib:<\/strong> Jiangsu HengRui Medicine Co., Ltd.<\/li>\n<li><strong>PD-0332991:<\/strong> Pfizer<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Liver Cancer market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/liver-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Liver Cancer Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Liver Cancer Market Strengths<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increasing incidence due to the change in lifestyle, increasing obesity etc<\/li>\n<li>Presence of a strong pipeline is expected to bring a positive change in the market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Liver Cancer Market Opportunities<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increase in awareness owing to the efforts being put in educating people about diseases plays an important part<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Liver Cancer Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Liver Cancer Companies:<\/strong> Pfizer, GlaxoSmithKline, Kyowa Kirin Co., Ltd., Hoffmann-La Roche, Eli Lilly and Company, Guerbet, CStone Pharmaceuticals, SOTIO Biotech, Akeso Biopharma, Adagene Inc., Tempest Therapeutics, Eximias Pharmaceutical, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Jiangsu HengRui Medicine Co., Ltd., and others<\/li>\n<li><strong>Key Liver Cancer Therapies:<\/strong> Sunitinib (SU011248), TSR-022 and TSR-042, ARQ197, bevacizumab [Avastin], Pemetrexed, Lipiodol, Nofazinlimab, Nanrilkefusp alfa (formerly SOT101), AK112, Bevacizumab, Tiragolumab, doxorubicin hydrochloride, exatecan mesylate, Brivanib, Apatinib, PD-0332991, and others<\/li>\n<li><strong>Liver Cancer Therapeutic Assessment:<\/strong> Liver Cancer current marketed and Liver Cancer emerging therapies<\/li>\n<li><strong>Liver Cancer Market Dynamics:<\/strong> Liver Cancer market drivers and Liver Cancer market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Liver Cancer Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Liver Cancer Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Liver Cancer companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/liver-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Liver Cancer Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Liver Cancer Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Liver Cancer<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Liver Cancer<\/p>\n<p style=\"text-align: justify;\">4. Liver Cancer Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Liver Cancer Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Liver Cancer Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Liver Cancer Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Liver Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Liver Cancer Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Liver Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Liver Cancer Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Liver Cancer Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Liver Cancer Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Liver Cancer Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Liver Cancer Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Liver Cancer Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Liver Cancer Appendix<\/p>\n<p style=\"text-align: justify;\">18. Liver Cancer Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=liver-cancer-market-and-epidemiology-forecast-2032-population-data-drugs-companies-and-competitive-intelligence-by-delveinsight-pfizer-glaxosmithkline-kyowa-kirin-co-ltd-hoffmannla-roche\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 8774225362<br \/><strong>Address:<\/strong>27 Drydock Ave  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Boston<br \/><strong>State:<\/strong> MA<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=liver-cancer-market-and-epidemiology-forecast-2032-population-data-drugs-companies-and-competitive-intelligence-by-delveinsight-pfizer-glaxosmithkline-kyowa-kirin-co-ltd-hoffmannla-roche\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cLiver Cancer Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Liver Cancer. DelveInsight&rsquo;s &ldquo;Liver Cancer Market Insights, Epidemiology, and Market Forecast-2032&Prime; report offers an in-depth understanding of the Liver Cancer, historical and forecasted epidemiology &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/liver-cancer-market-and-epidemiology-forecast-2032-population-data-drugs-companies-and-competitive-intelligence-by-delveinsight-pfizer-glaxosmithkline-kyowa-kirin-co-ltd-hoffmannla-roche_651209.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-651209","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/651209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=651209"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/651209\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=651209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=651209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=651209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}